Our Mission
Discover novel molecular targets in cancer cells and immunosuppressive and pro-tumorigenic tumor microenvironment and develop cutting-edge nanotherapeutic solutions for various solid and hematological cancers. We are committed to unraveling the complexities of cancer biology and cancer genetics for discovering novel molecular therapeutic targets (genes, non-coding RNAs, proteins) and develop next generation of highly targeted nanotherapeutics for cancer patients.
Our research is dedicated to three crucial avenues:
- Discovery of novel therapeutic targets using patient tumor databases and validation of these novel oncogenic molecular targets using genetic methods
- Development of novel targeted cancer therapeutics to block the activity of single or multiple oncogenic pathways, that we validate such as eEF2-kinase (eEF2K), FOXM1, AXL kinases, previously known oncogenic targets (i.e, KRAS) as well as immune suppressive pathways including PDL1, B7-H3 and IDO1 and tumor associated macrophages (TAMs) using highly targeted therapeutics.
- Generating highly effective and safe cancer nanotherapeutics and nanodrugs using lipids-based nanodelivery vehicles (i.e, nanoliposomes, immunoliposomes, micelles), polymer-based nanoparticle (ie. chitosan, albumin) and magnetic or metal-based nanocarriers (i.e, Iron-Fe oxide, Cobalt, gold and silver) for the delivery of various novel cancer therapeutics (i.e, small molecule inhibitors, microRNA, non-coding RNA, RNA or oligonucletide-based therapeutics, therapeutic peptides and chemical compounds).
0
Citations
0
H-Index
0
Research Outputs